MorphoSys Total Revenue vs Selling And Marketing Expenses Analysis
MOR Stock | USD 19.34 0.84 4.54% |
MorphoSys financial indicator trend analysis is infinitely more than just investigating MorphoSys AG ADR recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MorphoSys AG ADR is a good investment. Please check the relationship between MorphoSys Total Revenue and its Selling And Marketing Expenses accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MorphoSys AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
Total Revenue vs Selling And Marketing Expenses
Total Revenue vs Selling And Marketing Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MorphoSys AG ADR Total Revenue account and Selling And Marketing Expenses. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between MorphoSys' Total Revenue and Selling And Marketing Expenses is 0.47. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Selling And Marketing Expenses in the same time period over historical financial statements of MorphoSys AG ADR, assuming nothing else is changed. The correlation between historical values of MorphoSys' Total Revenue and Selling And Marketing Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of MorphoSys AG ADR are associated (or correlated) with its Selling And Marketing Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling And Marketing Expenses has no effect on the direction of Total Revenue i.e., MorphoSys' Total Revenue and Selling And Marketing Expenses go up and down completely randomly.
Correlation Coefficient | 0.47 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Revenue
Total revenue comprises all receipts MorphoSys AG ADR generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Selling And Marketing Expenses
Most indicators from MorphoSys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MorphoSys AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MorphoSys AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. At this time, MorphoSys' Selling General Administrative is relatively stable compared to the past year. As of 05/17/2024, Sales General And Administrative To Revenue is likely to grow to 0.38, though Tax Provision is likely to grow to (1.1 M).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 181.5M | 116.5M | 109.9M | 115.4M | Depreciation And Amortization | 98.4M | 10.5M | 10.5M | 10.4M |
MorphoSys fundamental ratios Correlations
Click cells to compare fundamentals
MorphoSys Account Relationship Matchups
High Positive Relationship
High Negative Relationship
MorphoSys fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 496.4M | 1.7B | 2.6B | 2.4B | 2.0B | 2.1B | |
Other Current Liab | 46.8M | 146.9M | 206.9M | 230.2M | 202.4M | 212.5M | |
Total Current Liabilities | 61.6M | 200.5M | 284.5M | 278.3M | 264.3M | 277.5M | |
Total Stockholder Equity | 394.7M | 621.3M | 244.9M | 157.4M | 49.0M | 46.6M | |
Property Plant And Equipment Net | 4.7M | 50.7M | 49.6M | 51.0M | 15.0M | 11.8M | |
Net Debt | (1.7M) | 208.4M | 202.5M | (62.9M) | 477.4M | 501.3M | |
Retained Earnings | (255.8M) | (157.9M) | (672.3M) | (823.4M) | (1.0B) | (962.5M) | |
Accounts Payable | 10.7M | 47.6M | 73.8M | 38.6M | 28.4M | 14.7M | |
Cash | 44.3M | 109.8M | 123.2M | 402.4M | 158.5M | 166.4M | |
Non Current Assets Total | 192.7M | 452.7M | 1.4B | 1.3B | 1.2B | 1.3B | |
Non Currrent Assets Other | 44.1M | 1.6M | 4.1M | 8.7M | 1.2M | 1.2M | |
Cash And Short Term Investments | 272.5M | 1.1B | 993.7M | 907.2M | 682.8M | 716.9M | |
Common Stock Total Equity | 29.4M | 31.8M | 32.0M | 32.9M | 37.8M | 34.8M | |
Common Stock Shares Outstanding | 31.6M | 132.7M | 133.6M | 136.6M | 137.3M | 103.8M | |
Liabilities And Stockholders Equity | 496.4M | 1.7B | 2.6B | 2.4B | 2.0B | 2.1B | |
Non Current Liabilities Total | 40.2M | 837.7M | 2.0B | 2.0B | 1.7B | 1.8B | |
Other Current Assets | (40.3K) | 10.0M | 15.9M | (367.0) | 24.0 | 22.8 | |
Other Stockholder Equity | 619.8M | 744.1M | 830.2M | 831.3M | 936.1M | 982.9M | |
Total Liab | 101.7M | 1.0B | 2.3B | 2.2B | 2.0B | 2.1B | |
Property Plant And Equipment Gross | 20.8M | 50.7M | 69.9M | 71.5M | 37.7M | 39.6M | |
Total Current Assets | 303.7M | 1.2B | 1.1B | 1.1B | 814.0M | 854.7M | |
Intangible Assets | 41.1M | 69.4M | 838.3M | 886.6M | 844.1M | 886.3M | |
Common Stock | 31.8M | 32.0M | 32.9M | 34.2M | 37.7M | 35.4M | |
Other Assets | 1.1M | 134.4M | 199.8M | 8.7M | 10.0M | 9.5M | |
Net Receivables | 20.3M | 89.8M | 85.8M | 112.4M | 42.7M | 83.8M | |
Inventory | 288.2K | 10.0M | 20.8M | 24.3M | 62.1M | 65.2M | |
Short Long Term Debt Total | 42.6M | 318.2M | 325.8M | 339.5M | 635.9M | 667.7M | |
Good Will | 3.7M | 1.6M | 335.6M | 356.2M | 342.3M | 359.4M | |
Accumulated Other Comprehensive Income | (1.3M) | 2.2M | 52.8M | 115.3M | 88.4M | 92.9M | |
Current Deferred Revenue | 1.6M | 2.5M | 223.9K | 19.4M | 17.5M | 18.4M | |
Short Term Investments | 228.2M | 980.5M | 870.4M | 504.8M | 524.3M | 372.9M | |
Short Term Debt | 2.5M | 3.5M | 3.7M | 9.6M | 14.1M | 14.2M | |
Other Liab | 138.1K | 523.0M | 1.7B | 1.6B | 1.9B | 2.0B | |
Net Tangible Assets | 349.9M | 550.3M | (929.0M) | (1.1B) | (976.9M) | (928.0M) | |
Long Term Debt | 0.0 | 272.8M | 282.8M | 291.6M | 613.1M | 643.7M | |
Long Term Investments | 96.0M | 99.0M | 196.6M | 5.4M | 3.6M | 3.4M | |
Property Plant Equipment | 47.8M | 50.7M | 49.6M | 51.0M | 58.6M | 61.6M | |
Capital Lease Obligations | 42.6M | 45.0M | 42.6M | 45.8M | 12.4M | 23.0M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MorphoSys AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for MorphoSys Stock analysis
When running MorphoSys' price analysis, check to measure MorphoSys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MorphoSys is operating at the current time. Most of MorphoSys' value examination focuses on studying past and present price action to predict the probability of MorphoSys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MorphoSys' price. Additionally, you may evaluate how the addition of MorphoSys to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is MorphoSys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MorphoSys. If investors know MorphoSys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MorphoSys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.87) | Earnings Share (1.49) | Revenue Per Share 1.7163 | Quarterly Revenue Growth 0.131 | Return On Assets (0.14) |
The market value of MorphoSys AG ADR is measured differently than its book value, which is the value of MorphoSys that is recorded on the company's balance sheet. Investors also form their own opinion of MorphoSys' value that differs from its market value or its book value, called intrinsic value, which is MorphoSys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MorphoSys' market value can be influenced by many factors that don't directly affect MorphoSys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MorphoSys' value and its price as these two are different measures arrived at by different means. Investors typically determine if MorphoSys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MorphoSys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.